Glaxosmithkline

This study is testing a new vaccine designed to protect infants from two dangerous types of Salmonella bacteria that can cause severe illness and typhoid fever. Researchers will give the vaccine to healthy babies in Africa, starting at either 6 weeks or 6 months old, to check if …

This study is testing a new version of a pneumonia vaccine called PnMAPS30plus in healthy adults aged 50 to 64. About 120 participants will receive one dose of either the new vaccine or an already approved one and be followed for about six months. The main goals are to check if t…

This study is testing a new combined vaccine against measles, mumps, rubella, and chickenpox (varicella) in healthy children. Researchers want to see if this new vaccine works as well as and is as safe as an existing licensed vaccine when given as a second dose. The study will in…

This early-stage study aims to check if a new experimental pneumonia vaccine is safe for toddlers. It will involve 45 healthy children aged 12-15 months who have already had their standard baby pneumonia shots. Researchers will compare side effects from the new vaccine to those f…

This study aims to check if a new experimental pneumonia vaccine is safe for babies. It will involve 60 healthy infants, starting at about 2 months old. Researchers will compare the new vaccine to an existing one, watching closely for any side effects like fever, redness, or slee…

This is an early-stage study to test a new vaccine designed to protect against both seasonal flu and COVID-19 with a single shot. It will involve 225 healthy adults aged 65 to 85. The main goals are to check if the vaccine is safe and to see how well it triggers the body's protec…

This study aims to see how long a vaccine against Shigella bacteria, a major cause of severe diarrhea, keeps working in African children. It will follow 528 children for up to three years after their last vaccine dose to measure their immune response. The study involves no new va…

This study is testing whether adding a new injectable medication called depemokimab to standard asthma care can help people with a specific type of asthma (Type 2) who are prone to serious flare-ups. About 456 adults and teenagers will receive either the new medication or a place…

This large, late-stage study aims to find out if a new drug called GSK5733584 works better than standard chemotherapy for women with ovarian cancer that has become resistant to platinum-based drugs. It will enroll about 450 participants to directly compare how long the cancer is …

This study is testing a new four-drug combination for adults recently diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. It is for people who are not candidates for a stem cell transplant. Researchers want to see if adding a new drug called belan…

This study is for adults whose multiple myeloma, a type of blood cancer, has returned or stopped responding to prior treatments. The main goal is to see if giving the drug belantamab mafodotin less frequently, in combination with other standard cancer drugs, can still effectively…

This large, late-stage study aims to find out if a new drug called GSK5733584 works better and is safer than standard chemotherapy for women whose endometrial cancer has returned. It will enroll about 600 participants whose cancer has come back after prior treatment. The main goa…

This is the first study in people for a new cancer drug called GSK5533524. It aims to find a safe dose and see how well adults with advanced solid tumors that have stopped responding to standard treatments can tolerate it. Researchers will also check if the drug can shrink tumors…

This is a first-in-human study to test the safety and tolerability of a new investigational drug called GSK5926371. It is designed for adults with autoimmune rheumatic diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The main goal is to find a safe …

This study is testing a new drug, GSK3862995B, to see if it can help adults with bronchiectasis, a long-term lung condition. The main goal is to see if the drug can reduce the number of times a person's symptoms suddenly get much worse, known as exacerbations. About 400 participa…

This early study aims to understand how children's bodies process a single dose of a new antibiotic called gepotidacin. It involves 20 hospitalized children aged 2-12 who are already receiving standard antibiotic treatment for confirmed or suspected infections. Researchers will m…